Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
HIV Diagnostics Market – Market Insights
HIV diagnostics plays a major role in HIV prevention, treatment, care, and other support services. The diagnosis of HIV include testing services in health-care facilities, and wide range of community-based approaches along with HIV self-testing.
The global HIV diagnostics market was valued at US$ 3,050.8 million in 2018, and is expected to exhibit a CAGR of 9.2% over the forecast period (2019-2027).
Figure 1. Global HIV Diagnostics Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2020)
Rising government initiatives are expected to boost growth of the HIV diagnostics market
HIV diagnostics market is expected to witness significant growth, owing to rising government initiatives, in order to control the HIV infection. For instance, in April 2017, Ministry of Health and Family Welfare, Government of India, launched ‘Test and Treat Policy for HIV’ policy, which is expected to improve longevity and quality of life of those infected with HIV. Moreover, in 2017, Ministry of Health, Sri Lanka initiated National HIV/STI Strategic Plan (NSP) Sri Lanka 2018-2022. This strategic plan include five objectives, which will support NSP’s vision to make country free from new HIV infections, discrimination, and AIDS related deaths.
Increasing demand for home testing HIV diagnosis is encouraging key manufacturers to focus on developing portable, easy-to-use, and rapid diagnosis test. This, in turn, is expected to boost the market growth. For instance, in November 2018, Atomo Diagnostics’ Atomo HIV Self-Test was approved for sale in Australia by the Therapeutic Goods Administration (TGA). It is the first and only diagnostic self-test for HIV to receive approval from Australia’s national regulator.
HIV diagnostics market is expected to witness significant growth, owing to increasing adoption of agreement and collaborations strategies by the market players. For instance, in September 2019, Mylan N.V. and Atomo Diagnostics entered into partnership. Under the partnership Mylan gained commercialization rights for Atomo’s HIV rapid diagnostic in Africa, Asia, Middle East, the Commonwealth of Independent States (CIS), and Latin America.
Rising number of HIV cases, which are undiagnosed or late diagnosed are driving demand for HIV diagnostics, which is further expected to bolster HIV diagnostics market growth over the forecast period. For instance, according to the European Centre for Disease Prevention and Control (ECDC) report 2017, around 51% of all HIV cases were diagnosed late, and around 28% had advanced HIV infection, when diagnosed in the Europe in 2015. Moreover, the proportion of those late diagnosis was over 50% in nine European countries, which include Austria, Estonia, Greece, Italy, Latvia, Lithuania, Romania, Slovenia, and Sweden.
Figure 2. Global HIV Diagnostics Market Share (%), by Product Type, 2019 and 2027
Source: Coherent Market Insights Analysis (2020)
HIV Diagnostics Market - Regional Analysis
North America held a dominant position in the global HIV diagnostics market in 2018, owing to increasing product approval in the region. For instance, in November 2019, Vela Diagnostics received de novo authorization by the U.S. Food and Drug Administration (FDA) for its Sentosa SQ HIV-1 Genotyping Assay developed for detection of HIV-1 genomic drug resistance mutations (DRMs). Moreover, in May, 2019, Abbott Laboratories received the World Health Organization's Prequalification approval (WHO PQ) for m-PIMA HIV-1/2 VL, the first point-of-care viral load diagnostic test. The portable molecular point-of-care test is designed specifically for usage in resource-limited settings. The prequalification status qualifies the product for purchase by agencies of the United Nation.
Moreover, Europe is expected to witness significant growth in the HIV diagnostics market during the forecast period, owing to rising product launches by the key players. For instance, in July 2018, Abbott Laboratories, launched m-PIMA HIV-1/2 VL, the first point-of-care viral load diagnostic test at the International AIDS Conference, held in Amsterdam in 2018.
Key Players
Major players operating in the global HIV diagnostics market include Abbott Laboratories, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myres Squibb, Janssen Therapeutic, QIAGEN N.V., and ViiV Healthcare Ltd.
US :
INDIA :
UK :
JAPAN :
U.S. :
+1-206-701-6702
UK :
+44-020-8133-4027
JAPAN :
+81-050-5539-1737
INDIA :
+91-848-285-0837
Sales Office (U.S.) : 
